|
Nexia Nexia Biotechnologies is one of the world`s largest producers of authentic recombinant spider silk, and a leading North American animal transgenic company. Nexia manufactures biomaterials and therapeutic proteins in the milk of transgenic dairy goats. This technology combines the large scale, cost-effective dairy infrastructure with recombinant DNA technology to produce rare, complex proteins. Infrastructure Nexia currently has 100 highly trained employees, a centralized head office and laboratories in the Montréal suburb of Vaudreuil-Dorion. Nexia supports 3 production farms, two situated on a 85 acre site in Québec and one situated on a 60 acre site in upstate New York. Nexia has recently completed an Initial Public Offering, raising $40 million CDN. Nexia is traded on the Toronto Stock Exchange (TSE) under the symbol NXB. It has received approximately $24.7 million from prominent investors such as MDS Capital Corp., Ontario Teacher`s Pension Plan, Société Innovatech du Grand Montréal, Royal Bank Ventures Inc., Sofinov (a subsidiary of the Caisse de dépôt et placement du Québec), the Canadian Medical Discoveries Fund, and four Asian investor groups, led by 1st BioVenture Capital Corp. Technical Expertise Nexia`s internationally respected team has special expertise in molecular and cellular biology, embryology, dairy science and animal husbandry, all key elements required for the production of recombinant proteins in the milk of transgenic animals. What Competitive Advantages Does Nexia Have? Nexia has developed proprietary technology which significantly reduces the time and cost to develop value-added products in the milk of transgenic BELE® goats. The BELE® (Breed Early, Lactate Early) goat system reduces the time to generate a transgenic goat as compared to standard goats or sheep. Prior to any animal work, the gene of interest is thoroughly characterized within Nexia`s patented mammary cell culture system (MAC-T) to improve the efficiency of rapid development. Nexia`s products include two classes of proteins: biomaterials - lead product - a recombinant spider silk (BioSteel®) and; pharmaceuticals - lead product - recombinant tPA (tissue plasminogen activator). |
|
| aus der Diskussion: | Nexia Biotech- große Zukunftsaussichten |
| Autor (Datum des Eintrages): | Bombenleger (01.12.02 13:55:37) |
| Beitrag: | 4 von 43 (ID:7983025) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |